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Summary: Purpose and Methods: During the intracarotid 
amobarbital procedure (IAP) at the University of Michigan, 
continuous scalp EEG monitoring guides the timing for pre- 
sentation of memory items and postinjection testing. Most of 
our patients have undergone bilateral injections. The interval 
between injections varied from 22 to 60 min, depending on the 
test and recovery time, as well as the time to catheterize the 
second side. After noting a trend toward prolonged electro- 
graphic recovery following the second injection, we tested our 
clinical impression that recovery of the second hemisphere may 
be influenced by (a) the time between injections and (b) which 
hemisphere is injected first (epileptogenic or nonepilepto- 
genic). 
To study these questions, we analyzed EEG recovery data 
from 48 consecutive IAPs. Approximately half the patients had 
the epileptogenic side injected first. 
Results: We found that (a) electrographic recovery after the 
second injection is prolonged if the interval between bilateral 
injections is less than 40 minutes and (b) electrographic recov- 
ery is more rapid after injection of the epileptogenic hemi- 
sphere. 
Conclusions: We now recommend waiting at least 45 min 
between injections. The pathophysiology of more prolonged 
amobarbital effect on the nonepileptogenic hemisphere than on 
the epileptogenic hemisphere remains unclear. Key Words: 
Amobarbital-Intracarotid-Epilepsy-Temporal lobe- 
Memory-Epilepsy partial-Injections-Intraarterial. 
For more than a decade, Wada's intracarotid amobar- 
bital test was used exclusively to localize language func- 
tion (1). In 1962, Milner (2) proposed that the procedure 
be used to identify patients at risk for anterograde global 
amnesia after anterior temporal lobectomy (ATL). While 
the role of the intracarotid amobarbital procedure (IAP) 
in localizing language function has remained largely un- 
changed, significant controversy has arisen about the 
value of the IAP in (a) noninvasive lateralization of the 
epileptogenic zone (3-7) and (b) prediction of postop- 
erative memory function (6,8,9). The role of the IAP in 
predicting both seizure outcome and postoperative cog- 
nition depends on consistent, accurate, bilateral memory 
testing during the procedure. To facilitate investigation 
of these issues, a standardized IAP protocol, with equiva- 
lent injections of the two hemispheres, must be devel- 
oped. 
At our institution, concurrent monitoring of EEG ac- 
tivities during the IAP has become an important tool for 
interpreting changes in the patient's level of alertness, 
excluding the possibility of ictal activity, and determin- 
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ing the extent of amobarbital effect in the hemisphere 
contralateral to injection. Previous studies have demon- 
strated an excellent correlation between the type of on- 
line visual analysis we perform and automated quantita- 
tive techniques (10). Data available during the IAP pro- 
vide the most useful information for optimizing the 
timing of injections and behavioral testing. Qualitative 
EEG has some additional advantages while the patient is 
being tested: (a) it allows the electroencephalographer to 
evaluate different types of artifact effectively (including 
myogenic, kinesogenic and oculomotor), (b) it allows the 
electroencephalographer some degree of ability to dis- 
tinguish between amobarbital-induced slowing and gen- 
eralized slowing at drowsiness, and (c) it provides very 
rapid indications of any of the patient's usual ictal 
events. 
Recently, we undertook an investigation of the optimal 
sequence and timing of bilateral IAPs. Traditionally, 
some centers have chosen to perform hemispheric injec- 
tions on separate days-apparently preferring to avoid 
potential interaction between serial injections, but risking 
an increased complication rate with separate catheriza- 
tion procedures. The overall morbidity data reported by 
Rausch (1 1) shows that 79% of centers have encountered 
a 0-1% risk, while 21% of centers reported a 1-5% 
incidence of morbidity. According to a survey of IAP 
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centers in 1992 (12), 60% of bilateral IAPs are per- 
formed on the same day, injecting the epileptogenic 
hemisphere first. A brief review of protocols for 10 ma- 
jor centers which recently published IAP data shows that 
3 perform the injections on subsequent days, 3 allow 
45-60 min before the second injection, and 4 wait s 3 0  
min between injections. 
At our center, preliminary investigation yielded an in- 
dication that (a) the electrographic recovery time after 
the nonepileptogenic hemisphere is injected may be 
longer than recovery after injection of the epileptogenic 
hemisphere and (b) the length of the interval between 
first and second injections might influence the rate of 
electrographic recovery after the second test. We were 
interested in investigating the optimal interval between 
the 2 injections-that is, to determine the waiting period 
that would eliminate the residual effect of the amobar- 
bital on electrographic changes and which might possi- 
bly, avoid behavioral dysfunction. 
METHODS 
Subjects 
A total of 48 patients had IAPs with complete EEG- 
CCTV monitoring at the University of Michigan be- 
tween April 1990 and April 1993. All were evaluated as 
part of an epilepsy surgery protocol for treatment of re- 
fractory partial epilepsy (13). The group, (Table l), in- 
cludes 26 males and 22 females. Epileptogenic zones 
were subsequently resected in all patients; there were 23 
right- and 25 left-sided resections. All of our patients had 
left-hemisphere language dominance or predominance, 
except for 1 right-handed woman, who had right- 
hemispheric language predominance. Pathologically, 10 
patients were found to have progressive or nonprogres- 
sive lesions, including 4 gliomas, 1 ganglioglioma, 2 
epidermoid cysts, 1 hamartoma, and 2 vascular malfor- 
mations. Six of the patients had only unilateral IAPs; 42 
bilateral tests were available for review. 
To minimize the risk of unexpected cognitive changes 
during localization procedures, we perform IAPs only 
after definitive identification of ictal onset zones, i.e., 
after any intracranial interventions that might alter func- 
tion of nonresected tissue. In 22 of the bilateral proce- 
dures performed, the epileptogenic hemisphere was in- 
TABLE 1. IAP demographics 
Sex 26 male 22 female 
Latenility of rchection 25 left 23 right 
Language predominance 4 1  left I right 
Pathology 38 mesial TLE I0 lesional 
Side of first injection 
Unilatcrallbilateral IAP 6 unilateral 42 bilateral 
(bilateral) 22 epileptiform 20 nonepileptiform 
IAP, intracarotid amoharbital procedure 
jected first, and in 20 others, the nonepileptogenic side 
was injected first. In cases with any bilateral ictal onsets, 
IAP data were reviewed after the procedure to evaluate 
the correspondence of ictal sampling and IAP testing in 
identifying the more dysfunctional hemisphere. 
IAP 
The IAP followed a standard protocol, a modification 
of the method pioneered at the Montreal Neurologic In- 
stitute (1 4). Following transfemoral catheterization, ma- 
chine-injected intracarotid angiography was carried out 
in each hemisphere immediately before manual injection 
of 125 mg of amobarbital in 5 cc sterile water over 3 s. 
Continuous EEG-CCTV monitoring began with a base- 
line 16-channel tracing for approximately 25 min before 
injection. The electrographic data were carefully moni- 
tored by a qualified electroencephalographer (TRH or 
LMS). At the time of the injection, the patient was asked 
to count, to grip both of the examiner’s hands continu- 
ously and to wiggle toes bilaterally. Behavioral assess- 
ment began with preinjection testing by a qualified neu- 
ropsychologist (HAB) and continued throughout the pro- 
cedure. 
When electrographic slowing over the injected hemi- 
sphere had dissipated from primarily delta to primarily 
theta frequencies (usually 2-3 min), 5 memory items 
were presented (rarely, the presentation had to be de- 
layed because the patient did not yet seem attentive). The 
test stimuli consisted of (a) an object viewed and pal- 
pated in the hand ipsilateral to the injection, (b) 2 simple 
line drawings, (c) a sentence spoken by the examiner and 
repeated by the patient if possible, and (d), a large word 
printed on a card. No items were presented after strength 
had recovered to three-fifths in the hand contralateral to 
injection. Periodic evaluation of motor and sensory func- 
tion and visual fields was conducted; motor function was 
assessed by a neurologist and recorded on the tracing by 
a technologist. Motor function was judged normal when 
grip strength and finger movements had returned to base- 
line. Assessment of both spontaneous and recognition 
memory was conducted after full motor recovery and 
after the return of a 10-s epoch of the patient’s usual 
baseline EEG frequencies. A “passing” grade was con- 
sidered to be convincing recall of 3 or more of the 5 
items. After the procedure, patients were questioned 
about any physical or cognitive changes noted. 
Analysis and statistics 
EEG paper tracings were reviewed retrospectively, 
blinded to patient identity or side of epileptogenesis. The 
mean and standard deviation of 6 electrographic and mo- 
tor variables were ascertained for each IAP. These vari- 
ables are: (a,b), time to return to baseline EEG for first 
and second injections; (c,d), time to return to baseline 
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motor abilities for first and second injections; and (e,f), 
time to deltdtheta transition for first and second injec- 
tions. Paired t-tests and Pearson correlation coefficients 
were used to investigate the possible effects of 3 factors 
on the time required for electrographic activity to return 
to baseline. Factors investigated included effects of first- 
versus second-side injection, epileptogenic versus non- 
epileptogenic side injection, and the relationship between 
dissipation of slowing and return to baseline. We exam- 
ined our data for information about whether EEG or 
motor testing showed faster resolution of amobarbital 
effects. A regression analysis, using the interval between 
injections as a predictor of the electrographic recovery to 
baseline, was also performed. 
RESULTS 
The means and SDs for recovery of motor function 
and return to normal electrographic baseline are listed by 
category in Table 2. Overall, the mean latency to motor 
recovery was 6.4 min, and the latency for return to elec- 
trographic baseline was 7.8 min. In only 3 cases out of 73 
with adequate documentation of motor recovery did mo- 
tor recovery occur after electrographic recovery. Motor 
recovery was clearly longer after the second injection 
than after the first (t = 3.23, p < 0.003). The side of 
injection did not have any influence on motor recovery 
time. 
In terms of electrographic recovery, the interval to 
dissipation of the initial high amplitude delta activity did 
not correlate with any of the following variables: (a) the 
hemisphere injected, (b) the side of epileptogenesis, (c) 
the degree of baseline hemispheric slowing, or (d) the 
interval between injections. Frequencies over the hemi- 
sphere contralateral to the injection were usually normal 
before memory items were presented and always re- 
turned to baseline long before the injected hemisphere 
did. Examination of the latency to resumption of normal 
baseline frequencies in the injected hemisphere revealed 
TABLE 2. Electrographic and motor recovery times (s) 
Mean + SD 
Electrographic 
Mean recovery to baseline EEG (all injections 
Left hemisphere recovery 
Right hemisphere recovery 
First hemisphere recovery 
Second hemisphere recovery 
Epileptogenic hemisphere recovery 
Nonepileptogenic hemisphere recovery 
Mean motor recovery (all injections) 
First hemisphere recovery 
Second hemisphere recovery 
Epileptogenic hemisphere recovery 
Nonepileptogenic hemisphere recovery 
Motor 
;) 465 k 121 
475 f 132 
457 k 113 
446 k 107 
487 k 134 
445 126 
488f  113 
382 k 114 
357 f 102 
408 k 121 
380 k 126 
387 f 113 
SD, standard deviation. 
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no significant difference in recovery times between the 
dominant and nondominant hemispheres. However, a 
significant difference was noted between recovery of the 
epileptogenic hemisphere and the nonepileptogenic 
hemisphere, with the slower recovery seen after injection 
of the nonepileptogenic hemisphere (t = 2.34, p < 
0.024). 
When the first and second injections were compared, a 
significant delay was observed in both motor and elec- 
trographic recovery times after the second injection. The 
duration of amobarbital-induced electrographic dysfunc- 
tion after the second test correlated with the time be- 
tween injections. The regression line suggested that re- 
covery was equivalent if 44 min or more had elapsed 
between injections (Fig. 1). We looked selectively at 
interinjection intervals of above and below 40 min, and 
were able to demonstrate that the delay in electrographic 
recovery after the second injection disappeared if the 
waiting time was a 4 0  min. 
We found that time to recovery to electrographic base- 
line was longer after the second injection, and also after 
injection of the nonepileptogenic hemisphere (Table 3). 
To determine whether the order of injection or the later- 
ality of the focus was the most important factor in re- 
covery delay, we performed 2 further analyses. First, we 
found that the interval between injections for IAPs where 
the epileptogenic hemisphere was injected first was no 
different from that of the interval between injections 
when the nonepileptogenic hemisphere was injected first. 
Next, we determined that recovery to baseline after the 
second injection was significantly longer only when the 
epileptiform hemisphere was injected first. Thus, we 
concluded that electrographic recovery was most 
strongly delayed when the nonepileptogenic hemisphere 
was injected, and that this effect was abolished by al- 
lowing 40-45 min to pass between injections. 
DISCUSSION 
Electrographic and motor recovery have proved to be 
complementary tools during the IAP. Previous studies 
(10) have indicated an excellent correlation between 
quantitative EEG and the on-line visual analysis that pro- 
vides helpful information during the procedure; our data 
and recent quantitative assessments at our center corre- 
late well with Bouwer’s findings. 
On-line EEG analysis can indicate the degree and du- 
ration of ipsilateral and contralateral amobarbital effect 
and can clarify whether the drug has bilateral effects in 
unresponsive patients. It also elucidates unusual behavior 
and excludes ictal activity. No memory items are pre- 
sented prior to the dissipation of high-amplitude, often 
diffuse, delta activity. At our center, motor function is 
used to gauge early recovery, and no memory items are 
presented after motor strength has returned to three-fifths 
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FIG. 1. Regression analysis of the re- 
lationship of time interval between in- 
jections and EEG recovery. Dashed 
lines are 95% confidence interval (CI) 
for regression line. 
-250u 300 2 0  2 5  3 0  35  40 45 50  5 5  60  65 
Time Between Injections (minutes) 
or more. Testing for recall of items presented during 
amobarbital effect is undertaken only after the EEG has 
returned to baseline. With our protocol, motor function 
was recovered earlier than electrographic activity in 70 
of 73 cases. 
Resumption of normal baseline electrographic activity 
after amobarbital injection is an important event for a 
number of reasons. In this series, EEG proved to be a 
significantly more sensitive indicator of resolution of 
amobarbital-induced cerebral dysfunction than did motor 
recovery. Other authors have suggested that behavioral 
or cognitive abilities may return significantly later than 
motor and even language function (15), and our EEG 
data provide indirect support for this conclusion. The 
behavioral significance of electrographic recovery is evi- 
dent in a study of short-term and long-term memory 
during IAP, which assessed recall of test items (a), while 
activities over the injected hemisphere were slowed, and 
(b), after electrocerebral function had returned to base- 
line (4). When subjects were tested before amobarbital 
effects had disappeared, memory scores did not clearly 
differentiate between epileptogenic and nonepilepto- 
genic hemispheres, whereas testing after the EEG re- 
turned to baseline demonstrated a significant asymmetry 
in the memory function of the seizure-prone hemisphere. 
Testing prior to resumption of baseline EEG activity 
might therefore underestimate memory risk after surgery 
and provide less useful information for centers using the 
IAP to help confirm lateralization of the epileptogenic 
zone. 
We observed a significantly longer latency to resump- 
tion of baseline electrographic activities following amo- 
barbital perfusion of the nonepileptogenic hemisphere 
than after perfusion of the epileptogenic hemisphere. 
Similar findings were previously mentioned by Rausch 
and colleagues (16). These unexplained observations 
contradict a naive expectation that the more dysfunc- 
tional hemisphere would be slower to recover from an 
exogenous perturbation, such as supraphysiologic con- 
centrations of a barbiturate receptor agonist. Given the 
widespread hemispheric amobarbital perfusion produced 
by intracarotid administration, the explanation of these 
observations might be approached in terms of mecha- 
nisms of recovery from amobarbital where they differ in 
the epileptogenic and nonepileptogenic hemispheres. 
Possible explanations of the briefer EEG and the motor 
effects of amobarbital on the epileptogenic hemisphere 
include: (a) a lower density of barbiturate receptors over 
critical regions of this hemisphere, (b) a lower affinity of 
barbiturate receptors for amobarbital over these regions, 
(c) a lower concentration of gamma-aminobutyric acid 
(GABA) over these regions (17), (d) other (unknown) 
mechanisms leading to slower reversal of late local ef- 
fects of amobarbital in the nonepileptogenic hemisphere, 
and (e) other (unknown) mechanisms for reversal of late 
amobarbital effect mediated by the hemisphere contra- 
lateral to injection (i.e., resulting in a slower recovery 
when the more intact, nonepileptogenic, hemisphere is 
injected). 
One can begin to distinguish between these potential 
explanations by assessing data from previous relevant 
studies. We have not seen reports of autoradiographic 
barbiturate ligand studies of resected tissue in partial 
epilepsies. However, the consistent colocalization of 
barbiturate receptors with GABA and central benzo- 
diazepine receptors (cBZRs) in the GABA, receptor- 
chloride ionophore complex (1 8) permits indirect assess- 
ment of barbiturate receptor concentrations in human 
tissue. Autoradiographic studies reveal consistent de- 
creases in GABA receptor and cBZR density in the hip- 
pocampus but not in the neocortex of temporal lobec- 
tomy specimens (19-21). Further, positron emission 
Epilepsia, Vol. 38, No. 12, 1997 
1298 L. M. SELWA ET AL. 
TABLE 3. Recovery time comparisons (paired t tests) 
p value t 
Electrographic recovery 




Interval between injections 
Difference in recovery time (second minus first injection) 
Motor recovery 
Epileptogenic first vs. nonepileptogenic first 
Epileptogenic first vs. nonepileptogenic first 




p = 0.027 2.30 
p = 0.024 2.34 
NS 
p = 0.024 2.34 
p = 0.003 3.23 
NS 
NS, not significant. 
tomography (PET) with the cBZR ligand ["Clflumaze- 
nil shows that cBZR density consistently is decreased 
in anterior mesial temporal regions and rarely decreased 
in temporal neocortex and extratemporal regions in 
limbic temporal lobe epilepsy (22,23). It is difficult to 
explain widespread hemispheric asymmetries in amo- 
barbital effect by highly focal hippocampal asymmetries 
in barbiturate receptor density or affinity. Previous stud- 
ies of hippocampal recordings (24) have documented 
local amobarbital effects, and quantitative intracra- 
nial recordings might help to clarify whether local li- 
gand-receptor interactions could affect the speed of re- 
covery. 
We have also explored the influence of successive IAP 
procedures on electrographic recovery time, and have 
found that the first injection can significantly delay the 
recovery to baseline EEG activities after a second injec- 
tion within 2040 min. This would imply some type of 
residual effect of the injection. Given the previous stud- 
ies by Rouleau (4) and Rausch (16), we feel it is possible 
that delayed electrographic recovery reflects slower cog- 
nitive recovery. It seems wisest to eliminate any potential 
behavioral effects of the first injection before testing the 
second hemisphere. Different centers have used a variety 
of techniques to improve same-day recovery, including 
the use of methohexital or titration of amobarbital doses. 
We have modified our practice to allow 45 min between 
injections. After 45 min, we found no electrographic evi- 
dence that the first injection influenced recovery from 
the second injection. Our data support the possibility that 
both intracarotid amobarbital procedures might reason- 
ably be performed with a single transfemoral catheriza- 
tion in one day. 
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